Is Phoenix Ascend FDA cleared?
+
No — Phoenix Ascend is a capstone platform, not a cleared medical device. It is architected to the patterns a cleared system would need (HIPAA-grade audit, layer isolation, reproducible deploys), but it is not a replacement for Medtronic's regulated clinical tooling.
Whose data flows through it?
+
For the capstone, synthetic and de-identified telemetry only. The platform is shaped so that real PHI could flow through it under a proper BAA — that's the point of the layered architecture and audit posture — but we do not run real patient data.
Why two apps instead of one?
+
Portal and Athena are different jobs for different audiences. Portal is the live clinical product, built for patients, caregivers, and clinicians. Athena is our internal analysis workbench for the clinical trial: it parses raw pump and CGM exports in the browser so the engineering team can validate Portal outputs against real device files without ever touching server-side PHI. Merging them would force one to carry the other's trust boundary.
What does "four-layer architecture" actually mean?
+
Device layer (simulated pumps and CGMs), API layer (authenticated ingress and service mesh), App layer (Portal plus the Athena trial workbench), Data layer (time-series store, warehouse, audit log). Each layer is versioned, observable, and deployable on its own — failure in one doesn't cascade.
Who is on the team?
+
Four seniors, one Medtronic sponsor, and a faculty advisor. Full bios live on the
Team page.
Can I read the architecture?
+
Yes — the
Architecture page walks through the four layers, the telemetry journey, and the stack with no hand-waving.